Allergen‐specific immunotherapy provides immediate, long‐term and preventive clinical effects in children and adults: the effects of immunotherapy can be categorised by level of benefit ‐the centenary of allergen specific subcutaneous immunotherapy

Wiley - 2012
Lars Jacobsen1,2, Ulrich Wahn3, M B Bilò4
1Research Centre for Prevention and Health, Glostrup University Hospital, Copenhagen, Denmark
2Allergy Learning and Consulting, Krokushaven 18, DK 2765 Smorum, Copenhagen, Denmark
3<idGroup xmlns="http://www.wiley.com/namespaces/wiley"><id type="grid" value="grid.418434.e"></id></idGroup>Children's Hospital CharitéVirchow KlinikumBerlinGermany
4Allergy Unit, Department Immunology, Allergy and Respiratory Diseases, University Hospital, Ancona, Italy

Tóm tắt

AbstractAllergen Specific Immunotherapy (SIT) for respiratory allergic diseases is able to significantly improve symptoms as well as reduce the need for symptomatic medication, but SIT also has the capacity for long‐term clinical effects and plays a protective role against the development of further allergies and symptoms. The treatment acts on basic immunological mechanisms, and has the potential to change the pathological allergic immune response. In this paper we discuss some of the most important achievements in the documentation of the benefits of immunotherapy, over the last 2 decades, which have marked a period of extensive research on the clinical effects and immunological background of the mechanisms involved. The outcome of immunotherapy is described as different levels of benefit from early reduction in symptoms over progressive clinical effects during treatment to long‐term effects after discontinuation of the treatment and prevention of asthma. The efficacy of SIT increases the longer it is continued and immunological changes lead to potential long‐term benefits. SIT alone and not the symptomatic treatment nor other avoidance measures has so far been documented as the therapy with long‐term or preventive potential. The allergic condition is driven by a subset of T‐helper lymphocytes (Th2), which are characterised by the production of cytokines like IL‐4, and IL‐5. Immunological changes following SIT lead to potential curative effects. One mechanism whereby immunotherapy suppresses the allergic response is through increased production of IgG4 antibodies. Induction of specific IgG4 is able to influence the allergic response in different ways and is related to immunological effector mechanisms, also responsible for the reduced late phase hyperreactivity and ongoing allergic inflammation. SIT is the only treatment which interferes with the basic pathophysiological mechanisms of the allergic disease, thereby creating the potential for changes in the long‐term prognosis of respiratory allergy. SIT should not only be recognised as first‐line therapeutic treatment for allergic rhinoconjunctivitis but also as secondary preventive treatment for respiratory allergic diseases.

Từ khóa


Tài liệu tham khảo

10.1046/j.1472-9725.2003.00060.x

10.1111/j.1398-9995.1999.tb04410.x

10.1111/j.1398-9995.2007.01551.x

10.1111/j.1398-9995.2007.01620.x

10.1111/j.1399-3038.2009.00891.x

10.1111/j.1365-2222.2005.02251.x

10.1034/j.1398-9995.2002.23664.x

10.2500/108854194778816634

10.1067/mai.2002.121317

10.1016/S0091-6749(95)70235-0

10.1016/S1081-1206(10)62674-9

10.1034/j.1398-9995.2003.23639.x

10.1016/j.iac.2011.05.001

10.1016/S1081-1206(10)62194-1

10.1016/S0140-6736(00)78276-6

10.1038/nri1934

10.1016/j.jaci.2010.10.034

Committee for Medicinal Products for Human Use, 2008, Guideline on the Clinical Development of Products for Specific Immunotherapy for the Treatment of Allergic Diseases, European Medicines Agency

Committee for Medicinal Products for Human Use, 2008, Guideline on Allergen Products: Production and Quality Issues, European Medicines Agency

10.1067/mai.2001.118891

10.1111/j.1398-9995.2006.01312.x

Batemann ED, 2009, GINA No 95‐3659, 1

10.1111/j.1365-2222.2008.02976.x

10.1111/j.1398-9995.2010.02535.x

10.1111/j.1365-2222.2011.03804.x

10.1016/j.jaci.2007.01.045

10.1016/0091-6749(88)90021-8

10.1111/j.1398-9995.1995.tb01170.x

10.1067/mai.2001.112027

10.1111/j.1365-2222.1997.tb01252.x

10.1016/S0091-6749(97)70106-4

10.1067/mai.2001.115483

10.1046/j.1365-2567.2002.01338.x

10.1016/j.anai.2011.05.017

10.1111/j.1365-2222.2009.03207.x

10.1016/j.jaci.2010.12.1080

10.1016/S0091-6749(96)70205-1

10.1111/j.1398-9995.2006.01206.x

10.4049/jimmunol.172.5.3252

10.1016/j.jaci.2008.01.072

10.1002/eji.200322919

10.1172/JCI200423595

10.1016/j.jaci.2010.11.030

10.1067/mai.2000.107931

10.1111/j.1365-2222.2008.03020.x

10.1016/S0091-6749(03)02022-0

10.1159/000094714

Neerven RJ, 1999, Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum‐IgE‐facilitated allergen presentation, J Immunol, 163, 2944, 10.4049/jimmunol.163.5.2944

10.1111/j.1365-2222.2010.03462.x

10.1016/j.jaci.2011.03.049

10.1111/j.1398-9995.2005.00790.x

10.1034/j.1398-9995.2002.1o3532.x

10.1046/j.1398-9995.2003.00334.x

Williams A, 2007, Additional benefit of a third year of specific grass pollen allergoid immunotherapy in patients with seasonal allergic rhinitis, Eur Ann Allergy Clin Immunol, 39, 123

10.1016/j.jaci.2005.11.014

10.1016/j.jaci.2006.07.043

10.1056/NEJM199908123410702

10.1016/j.jaci.2009.10.035

10.1002/14651858.CD001936.pub2

10.1002/14651858.CD002893.pub2

10.1002/14651858.CD001186.pub2

10.1111/j.1398-9995.2006.01088.x

10.1016/j.jaci.2010.06.002

10.1185/03007990902820733

10.1586/17476348.1.1.65

Jacobsen L, 2009, Primary and secondary endpoints in clinical trials, Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M, 96, 96

10.1016/j.iac.2011.02.004

10.1111/j.1365-2222.2010.03521.x

10.1111/j.1398-9995.2010.02413.x

10.1111/j.1398-9995.2010.02531.x

10.1111/j.1398-9995.2010.02434.x

10.1136/bmj.302.6771.265

10.1111/j.1365-2222.1997.tb01225.x

10.1016/j.jaci.2006.05.003

10.1016/j.jaci.2007.07.046

10.1016/S0301-0546(03)79195-2

10.2500/aap.2011.32.3453

10.1111/j.1398-9995.1998.tb03969.x

10.1016/j.otohns.2005.07.020

10.1007/BF03370748

10.1016/j.jaci.2005.06.004

10.1016/0091-6749(91)90417-M

10.1016/0091-6749(93)90190-Q

10.1111/j.1398-9995.1997.tb00991.x

10.4168/aair.2009.1.1.3

10.1111/j.1365-2249.2010.04106.x

10.1016/j.jaci.2007.10.039

10.1111/j.1398-9995.1996.tb04655.x

10.1111/j.1398-9995.2006.01068.x

10.1111/j.1398-9995.2007.01451.x

10.1016/j.jaci.2011.12.973

10.1111/j.1398-9995.1988.tb01631.x

10.1111/j.1398-9995.1997.tb01251.x

10.1016/S0091-6749(95)70223-7

Des‐Roches A, 1996, Immunotherapy with a standardized Dermatophagoides pteronyssinus extract, V Duration of the efficacy of immunotherapy after its cessation Allergy, 51, 430

Kettner J, 2011, Considerable 6 years post treatment long‐term effect of pre‐seasonal subcutaneous specific immunotherapy (SCIT) with a high‐dose hypoallergenic grass pollen preparation. [abstract], Allergy, 66, 296

10.1034/j.1398-9995.2002.1o3264.x

10.1111/j.1398-9995.2006.01011.x

10.1016/j.jaci.2004.07.012

Johnstone DE, 1968, The value of hyposensitization therapy for bronchial asthma in children‐a 14‐year study, Pediatrics, 42, 793, 10.1542/peds.42.5.793

10.1164/ajrccm.162.6.9909087

Johnstone DE, 1961, Value of hyposensitization therapy for perennial bronchial asthma in children, Pediatrics, 61, 44

10.1016/S0091-6749(97)70069-1

10.1046/j.1365-2222.2001.01161.x

10.1046/j.1365-2222.2001.01027.x

10.1111/j.1398-9995.2004.00508.x

World Health Organization, 2002, Prevention of Allergy and Allergic Asthma, WHO report

1998, Allergic factors associated with the development of asthma and the influence of cetirizine in a double‐blind, randomised, placebo‐controlled trial: first results of ETAC, Early Treatment of the Atopic Child. Pediatr Allergy Immunol., 9, 116

10.1056/NEJMoa054692

10.1056/NEJMoa051378

Thông tin
Thông tin xuất bản

Wiley

Thông tin tác giả